Surgical Outcome Of da Vinci Single-port Surgical System In Lung Cancer

NCT07790406 | Recruiting

• 2 other identifiers: UID 5326L2-567
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Early-stage lung cancer represents a clinical challenge that, when diagnosed promptly, offers high chances of cure through lobectomy and lymphadenectomy. In addition to traditional surgery, robotic techniques have become established and have recently evolved further with the Single-Port system, which allows the procedure to be performed through a single subcostal incision rather than multiple openings between the ribs. This approach reduces invasiveness, postoperative pain, and recovery time, while maintaining the same oncological effectiveness and safety as standard techniques. This is a monocentric and non-profit collection of clinical data, both prospective and retrospective, from patients treated with this method, ensuring data privacy through coded information and compliance with current regulations; the study is independent and non-profit.

Conditions

Lung Cancer (NSCLC)

Keywords

lung cancer; surgery

Outcome Measures

Primary Outcomes (1)

• Evaluation of experience

  The objective of this study is to collect and describe IEO experiences in the use of the Da Vinci SP surgical system for anatomical lung resection.

  "From enrollment to the end of 5 year follow-up

Study Arms (1)

Surgical patient

Procedure: da Vinci Single Port

Interventions

da Vinci Single Port PROCEDURE

U-RATS lobectomy

Surgical patient

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study will include all patients with proven non-small cell lung cancer (NSCLC) clinical stage I (9th TNM edition), who have undergone or will undergo lobectomy plus radical lymph node dissection following the STS guide line

You may qualify if:

• all patients with proven non-small cell lung cancer (NSCLC) clinical stage I (9th TNM edition), who have undergone or will undergo lobectomy plus radical lymph node dissection following the STS guide line

You may not qualify if:

• no consent

Sponsors & Collaborators

• European Institute of Oncology: lead

Study Sites (1)

Istituto Europeo di Oncologia

Milan, Mi, 20141, Italy

RECRUITING

MeSH Terms

Conditions

Lung Neoplasms; Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms

Central Study Contacts

Monica Casiraghi, MD PhD

CONTACT

025748662; monica.casiraghi@ieo.it

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 16, 2026
• First Posted: August 27, 2026
• Study Start: February 2, 2026
• Primary Completion (Estimated): March 1, 2032
• Study Completion (Estimated): December 1, 2032
• Last Updated: August 27, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will share

Locations

IT (1)